Bronchogenic carcinoma after solid organ transplantation Marc de Perrot, MD, Dennis A Wigle, MD, Andrew F Pierre, MD, Ming S Tsao, MD, Thomas K Waddell, MD, Thomas R.J Todd, MD, Shaf H Keshavjee, MD The Annals of Thoracic Surgery Volume 75, Issue 2, Pages 367-371 (February 2003) DOI: 10.1016/S0003-4975(02)04379-5
Fig 1 Genotyping of normal donor lung tissue, the tumor, and recipient blood was performed to determine the origin of the lung tumor in the lung transplant recipient. (Recipient contribution is in black and donor contribution is in gray). A total of 8 different DNA loci were examined, of which 3 (A–C) are represented here. Calculation of the genetic contribution of the tumor demonstrated that approximately 70% of the tumor cells were from the donor (D). The remaining cells were from the recipient and included mainly inflammatory cells, which were also present in the normal donor lung tissue. The Annals of Thoracic Surgery 2003 75, 367-371DOI: (10.1016/S0003-4975(02)04379-5)
Fig 2 Tissue section from the bronchoalveolar carcinoma originating in the lung transplant recipient (hematoxylin & eosin, ×400). Genotyping indicated that approximately 70% of the tumor cells were from the donor, whereas the remaining contribution was from the recipient and included mainly inflammatory cells that infiltrated the normal donor lung tissue and the tumor. The Annals of Thoracic Surgery 2003 75, 367-371DOI: (10.1016/S0003-4975(02)04379-5)